Design of potent and selective human cathepsin K inhibitors that span the active site

被引:120
作者
Thompson, SK
Halbert, SM
Bossard, MJ
Tomaszek, TA
Levy, MA
Zhao, BG
Smith, WW
Abdel-Meguid, SS
Janson, CA
D'Alessio, KJ
McQueney, MS
Amegadzie, BY
Hanning, CR
DesJarlais, RL
Briand, J
Sarkar, SK
Huddleston, MJ
Ijames, CF
Carr, SA
Garnes, KT
Shu, A
Heys, JR
Bradbeer, J
Zembryki, D
Lee-Rykaczewski, L
James, IE
Lark, MW
Drake, FH
Gowen, M
Gleason, JG
Veber, DF
机构
[1] SmithKline Beecham Pharmaceut, Dept Med Chem, King Of Prussia, PA 19406 USA
[2] SmithKline Beecham Pharmaceut, Dept Mol Recognit, King Of Prussia, PA 19406 USA
[3] SmithKline Beecham Pharmaceut, Dept Macromol Sci, King Of Prussia, PA 19406 USA
[4] SmithKline Beecham Pharmaceut, Dept Prot Biochem, King Of Prussia, PA 19406 USA
[5] SmithKline Beecham Pharmaceut, Dept Gene Express Sci, King Of Prussia, PA 19406 USA
[6] SmithKline Beecham Pharmaceut, Dept Phys & Struct Chem, King Of Prussia, PA 19406 USA
[7] SmithKline Beecham Pharmaceut, Dept Radiochem, King Of Prussia, PA 19406 USA
[8] SmithKline Beecham Pharmaceut, Dept Cellular Biochem, King Of Prussia, PA 19406 USA
关键词
D O I
10.1073/pnas.94.26.14249
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Potent and selective active-site-spanning inhibitors have been designed for cathepsin K, a cysteine protease unique to osteoclasts. They act by mechanisms that involve tight binding intermediates, potentially on a hydrolytic pathway. X-ray crystallographic, MS, NMR spectroscopic, and kinetic studies of the mechanisms of inhibition indicate that different intermediates or transition states are being represented that are dependent on the conditions of measurement and the specific groups flanking the carbonyl in the inhibitor. The species observed crystallographically are most consistent with tetrahedral intermediates that may be close approximations of those that occur during substrate hydrolysis. Initial kinetic studies suggest the possibility of irreversible and reversible active-site modification. Representative inhibitors have demonstrated antiresorptive activity both in vitro and in vivo and therefore are promising leads for therapeutic agents for the treatment of osteoporosis. Expansion of these inhibitor concepts can be envisioned for the many other cysteine proteases implicated for therapeutic intervention.
引用
收藏
页码:14249 / 14254
页数:6
相关论文
共 26 条
[1]  
AMOS HE, 1985, IMMUNOTOXICOLOGY IMM, P207
[2]   From poor substrates to good inhibitors: Design of inhibitors for serine and thiol proteases [J].
Baggio, R ;
Shi, YQ ;
Wu, YQ ;
Abeles, RH .
BIOCHEMISTRY, 1996, 35 (11) :3351-3353
[3]   Proteolytic activity of human osteoclast cathepsin K - Expression, purification, activation, and substrate identification [J].
Bossard, MJ ;
Tomaszek, TA ;
Thompson, SK ;
Amegadzie, BY ;
Hanning, CR ;
Jones, C ;
Kurdyla, JT ;
McNulty, DE ;
Drake, FH ;
Gowen, M ;
Levy, MA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (21) :12517-12524
[4]  
BROMME D, 1993, J BIOL CHEM, V268, P4832
[5]  
Demuth H U, 1990, J Enzyme Inhib, V3, P249, DOI 10.3109/14756369009030375
[6]   Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts [J].
Drake, FH ;
Dodds, RA ;
James, IE ;
Connor, JR ;
Debouck, C ;
Richardson, S ;
LeeRykaczewski, E ;
Coleman, L ;
Rieman, D ;
Barthlow, R ;
Hastings, G ;
Gowen, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (21) :12511-12516
[7]  
Fink A L, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P177
[8]  
Foged NT, 1996, J BONE MINER RES, V11, P226
[9]  
Laskowski M Jr, 1986, Adv Exp Med Biol, V199, P1
[10]   Structure-based design of parasitic protease inhibitors [J].
Li, RS ;
Chen, XW ;
Gong, BQ ;
Selzer, PM ;
Li, Z ;
Davidson, E ;
Kurzban, G ;
Miller, RE ;
Nuzum, EO ;
McKerrow, JH ;
Fletterick, RJ ;
Gillmor, SA ;
Craik, CS ;
Kuntz, ID ;
Cohen, FE ;
Kenyon, GL .
BIOORGANIC & MEDICINAL CHEMISTRY, 1996, 4 (09) :1421-1427